Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Geron Corp GERN

Alternate Symbol(s): GERNW

Healthcare Biotechnology

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

NDAQ:GERN - Post by User

Geron Corp

<< Previous

Bullboard Posts

Next >>

Post by ChartEagle705on Nov 21, 2024 7:44am

24 Views

Post# 36323305

Short Short Short

The chart shows a clear downtrend, and I can see that the price has already made a new low and is now in a correction. I'm entering a short position from the $4.05 level with a stop at $4.10. I'll hold the take-profit target until liquidity at the $3.23 level

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks